#Yescarta

The personalized CAR-T therapy prolonged cancer remission compared with standard therapy.

Researchers are examining opportunities for immune-modulating approaches to improve outcomes and reduce side effects.

The CAR-T therapy led to complete remission in 60% of people with relapsed or refractory follicular lymphoma.

Yescarta led to complete remission in people with advanced non-Hodgkin lymphoma.

Tecartus led to durable remission in a majority of participants in a Phase II study.

The program will pay 65% of the cost of providing the custom-made immunotherapy.

We asked the experts what they think will be the next big breakthroughs.

The approved therapies have roiled the insurance approval process, which has led to delays and denials of coverage.

Cancer progress report highlights life-saving potential of immunotherapy, critical role of federal funding.

This approach has the potential to challenge the way cancer research is usually now done, one body part at a time.

Cutting-edge approach creates customized therapy.

Immunotherapy gives people with advanced lymphoma another treatment option.

Long-term follow-up from ZUMA-1 trial shows patients remain cancer-free for up to two years.

Yescarta is the first chimeric antigen receptor T cell (CAR-T) immunotherapy approved for adults.